Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress
Acceleron Pharma Inc. (Nasdaq: XLRN) announced the presentation of multiple abstracts on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress, scheduled for June 9-17. Highlighting the event, results from the BEYOND Phase 2 trial in adults with non-transfusion dependent beta-thalassemia will be shared during the Presidential Symposium on June 11. CEO Habib Dable expressed pride in presenting new data supporting luspatercept's efficacy and safety.
- Presentation at the prestigious EHA2021 enhances visibility for luspatercept.
- Data from the Phase 2 BEYOND trial highlights potential benefits for beta-thalassemia patients.
- None.
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that multiple abstracts on REBLOZYL® (luspatercept-aamt) will be presented at the upcoming 2021 European Hematology Association (EHA2021) Virtual Congress, to be held from June 9-17.
Of particular note, results from the BEYOND Phase 2 trial of luspatercept in adults with non-transfusion dependent beta-thalassemia will be presented on Friday, June 11th, during the Presidential Symposium, which honors the top six research papers submitted for presentation at the meeting.
“It’s a privilege to have such a prominent platform from which to share exciting new data on the effects of luspatercept in a patient population long in need of new therapeutic options,” said Habib Dable, President and Chief Executive Officer of Acceleron. “Moreover, it’s quite gratifying to present additional research that helps further establish luspatercept’s efficacy and safety profile.”
Presentations at EHA2021
Title: |
The BEYOND Study: Results of a Phase 2, double-blind, randomized, placebo-controlled multi-center study of luspatercept in adult patients with non-transfusion dependent beta-thalassemia – Abstract: S101 |
||
|
|
||
Session: |
Presidential Symposium |
||
Date: |
June 11, 2021 |
||
Time: |
4:00 p.m. to 5:30 p.m. CEST |
||
|
|
||
Title: |
Fewer red blood cell transfusion units and visits across baseline transfusion burden levels in patients with beta-thalassemia treated with luspatercept in the Phase 3 BELIEVE trial – Abstract: e-Poster 1304 |
||
|
|
||
Session: |
Thalassemias |
||
|
|
||
Title: |
Long-term efficacy and safety outcomes in the Phase 2 study of luspatercept in beta-thalassemia – Abstract: e-Poster 1305 |
||
|
|||
Session: |
Thalassemias |
||
|
{
"@context": "https://schema.org",
"@type": "FAQPage",
"name": "Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress FAQs",
"mainEntity": [
{
"@type": "Question",
"name": "What is the significance of the BEYOND Phase 2 trial results for XLRN?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The BEYOND Phase 2 trial results are significant as they will be showcased at the EHA2021, potentially influencing investor perception and future sales for luspatercept."
}
},
{
"@type": "Question",
"name": "When will Acceleron Pharma present results at EHA2021?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Acceleron Pharma will present results from the BEYOND trial on June 11, 2021, during the Presidential Symposium."
}
},
{
"@type": "Question",
"name": "What is luspatercept-aamt and its relevance to XLRN?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Luspatercept-aamt is a therapeutic developed by Acceleron Pharma for treating beta-thalassemia, with ongoing trials supporting its efficacy."
}
},
{
"@type": "Question",
"name": "How does the EHA2021 presentation impact XLRN investors?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Presenting at EHA2021 can enhance investor confidence in XLRN by showcasing advancements and support for luspatercept's therapeutic profile."
}
},
{
"@type": "Question",
"name": "What abstracts will be presented for XLRN at the EHA2021?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Abstracts presented include results from the BEYOND Phase 2 trial and additional research on luspatercept's efficacy in beta-thalassemia."
}
}
]
}
FAQ
What is the significance of the BEYOND Phase 2 trial results for XLRN?
The BEYOND Phase 2 trial results are significant as they will be showcased at the EHA2021, potentially influencing investor perception and future sales for luspatercept.
When will Acceleron Pharma present results at EHA2021?
Acceleron Pharma will present results from the BEYOND trial on June 11, 2021, during the Presidential Symposium.
What is luspatercept-aamt and its relevance to XLRN?
Luspatercept-aamt is a therapeutic developed by Acceleron Pharma for treating beta-thalassemia, with ongoing trials supporting its efficacy.
How does the EHA2021 presentation impact XLRN investors?
Presenting at EHA2021 can enhance investor confidence in XLRN by showcasing advancements and support for luspatercept's therapeutic profile.
What abstracts will be presented for XLRN at the EHA2021?
Abstracts presented include results from the BEYOND Phase 2 trial and additional research on luspatercept's efficacy in beta-thalassemia.
XLRN
NASDAQ:XLRNXLRN RankingsXLRN Latest NewsNov 22, 2021
Merck Completes Acquisition of Acceleron Pharma Inc.
XLRN Stock Data |